parameters correlated well with each other in ectopic ACTH-syndrome and Cushing's disease.
However, in adrenal cancer, urinary 17OHCS did not correlate with either plasma cortisol or urinary free cortisol , while the latter two parameters did.
During o,p'-DDD, urinary 17OHCS rapidly declined in a patient with ectopic ACTH syndrome and a patient with Cushing's disease before plasma cortisol or urinary free cortisol decreases . Consequently the positive correlations of urinary 17OHCS with the other parameters were lost. In a case of adrenal cancer, urinary 17OHCS again did not correlate with plasma cortisol or urinary free cortisol. In these conditions, plasma cortisol and urinary free cortisol still significantly correlated.
The present results demonstrated the limit of urinary 17OHCS as the index of the cortisol secretion rate both in some cases of adrenal cancer and in patients taking o,p'-DDD.
It is suggested that urinary free cortisol should be utilized as a more accurate index for the cortisol secretion rate in such circumstances.
o,p'-DDD, 2,2-bis (2-chloropheny1-4-chlorophenyl1)-1,1-dichloroethane, first discovered by Nelson and Woodard (1949) as an agent having cytotoxicity for the adrenal cortex of the dog, has been used for the treatment of metastatic adrenal cancer (Hutter and Kayhoe, 1966) as well as Cushing's disease (Luton et al., 1979) . This drug was reported to have adrenocorticolytic activity as well as steroid biosynthesis-blocking activity (Hart and Straw, 1971a; Hart et al., 1971b To further study the effects of o,p'-DDD on cortisol metabolism, correlations of each parameter before and during o,p'-DDD were compared. In these studies, data from case 1 and case 2 were analysed independently and also later combined as ACTH-dependent hypercortisolism, while those of case 3 were examined singly as adrenal-dependent hypercortisolism. Figure 4 demonstrates the correlation between the plasma cortisol concentration in the morning and urinary 170HCS excretion on the day of cortisol determination. Before o,p'-DDD, a positive correlation was obtained in both case 1 (r=0.703, P<0.005) and case 2 (r=0.809, P<0.05) or when their data were combined as ACTHdependent Cushing's syndrome (Fig. 4A , r= 0.826, P<0.001).
However, these correlations were lost during o,p'-DDD (Fig. 4A') . In a patient with adrenal cancer, no significant correlation was observed between the two parameters either before (Fig. 4B) or during (Fig. 4B') o,p'-DDD. Figure 5 shows the correlation between urinary excretions of 17OHCS and free cortisol. Although the number of determination was small, there was observed a close correlation before o,p'-DDD in case 1 (r= 0.933, P<0.01) or when data from case 1 and case 2 were combined (Fig. 5A , r= 0.957, P<0.001). These correlations were again lost during o,p'-DDD (Fig. 5A') . On the other hand, no significant correlation was observed in a patient with adrenal cancer either before (Fig. 5B) or during (Fig. 5131) o,p'-DDD. Figure 6 demonstrates the relationship between the plasma cortisol concentration and urinary free cortisol excretion on the day before o,p'-DDD administration.
In case 1 with ectopic ACTH syndrome, they correlated well (Fig. 6A, r=0 .913, P<0.05). Also in adrenal cancer, they demonstrated weak but significant correlation (Fig. 6B Notations are the same as in Fig. 1 . urinary 17OHCS excretion did not (Fig. 4) . Figure 7 shows the relationship between the plasma cortisol concentration and urinary free cortisol excretion during o,p'-DDD administration.
To assure the result, urinary 
Discussion
O,p'-DDD apparently has adrenocorticolytic activity as well as steroid-synthesisblocking activity (Hart and Straw, 1971 a; Hart et al., 1971b) .
Such observations were also made in our case 1 and case 3 with long term treatment.
In addition, the drug has been reported to have variable effects on the extra-adrenal steroid metabolism. (Murphy et al., 1981 ) the superiority of urinary cortisol to 17OHCS as a parameter of the cortisol secretion rate was demonstrated in the diagnosis of Cushing's syndrome (Eddy et al., 1973; Trecan et al., 1983; Zadik et al., 1980) . Nevertheless only few data have been presented on the clinical significance of urinary free cortisol during o,p'-DDD. Luton et al. (1979) reported a significant decrease in urinary excretion of 17OHCS, but not of free cortisol, within 2 weeks after o,p'-DDD administration. However, both parameters significantly decreased after mid-term therapy with o,p'-DDD (mean, 8 months). Their findings are compatible with ours, while they did not examine the correlations between various parameters of cortisol metabolism.
In the clinical situations described above, urinary 17OHCS cannot be a reliable index of cortisol secretion rate. Although the plasma cortisol concentration fluctuates widely and therefore sometimes may not reflect cortisol secretory status as a whole (deLacerda et al., 1973; Hellman et al., 1970; Krieger et al., 1971; Weitzman et al., 1971) , the present correlation between the plasma cortisol concentration and urinary free cortisol suggests the superiority of the latter to urinary 17-OHCS. Therefore, we believe that physicians should utilize urinary free cortisol as the most reliable index of the cortisol secretion rate in assessing the effects of o,p'-DDD and the cortisol metabolism in Cushing's syndrome of various etiology.
